IRIS
RAVELLI, ANGELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 37.585
Totale 37.585
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 37.585
Totale 37.585
Salva come PNG Salva come JPEG
Città #
Genova 27.301
Rapallo 4.086
Genoa 3.256
Vado Ligure 2.854
Bordighera 88
Totale 37.585
Salva come PNG Salva come JPEG
Nome #
Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. 244
Malattia di Menetrier e gastropatia ipertrofica proteino-disperdente transitoria del bambino: due entità cliniche distinte? 189
Novel automated system for Magnetic Resonance Imaging quantification of the inflamed synovial membrane volume in patients with juvenile idiopathic arthritis. 187
Inactive disease and remission in childhood-onset systemic lupus erythematosus. 181
A longitudinal printo study on growth and puberty in juvenile systemic lupus erythematosus. 168
Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. 162
HRCT and pulmonary function tests in monitoring of lung involvement in juvenile systemic sclerosis. 161
Juvenile Idiopathic Arthritis: Diagnosis and Treatment 161
Parent and child acceptable symptom state in juvenile idiopathic arthritis. 160
ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study 154
A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis 153
Should children and adolescents with systemic lupus erythematosus be given statin therapy to prevent early atherosclerosis? 151
Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study. 150
Ultrasound-detected synovial abnormalities are frequent in clinically inactive juvenile idiopathic arthritis, but do not predict a flare of synovitis. 150
The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 149

Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Assessment of Disease Activity in Patients with Juvenile Idiopathic Arthritis 148
Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. 148
MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis. 148
Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European League against Rheumatism evidence-based recommendations. 147
Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. 146
Agreement among musculoskeletal pediatric specialists in the assessment of radiographic joint damage in juvenile idiopathic arthritis. 145
Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. 144
Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis 144
Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference 143
A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. 141
Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. 135
Marked and sustained improvement 2 years after autologous stem cell transplantation in a girl with systemic sclerosis. 135
Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 134
Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. 133
Prevalence of anticardiolipin antibodies in juvenile chronic arthritis. 133
Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial 133
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept 133
High prevalence of antiphospholipid antibodies in children with idiopatic cerebral ischemia 132
Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. 132
Comparison of clinical versus ultrasound determined synovitis in juvenile idiopathic arthritis. 132
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis 132
The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. 132
Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. 131
Antiphospholipid antibody syndrome in pediatric patients. 131
Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. 131
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 131
Hypocomplementemic urticarial vasculitis syndrome with severe systemic manifestations 131
Aortic valve regurgitation as the presenting sign of Takayasu arteritis. 130
Patterns of clinical remission in select categories of juvenile idiopathic arthritis 129
Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases 129
Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 129
Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study 129
Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome 129
Neurological disorders, other than stroke, associated with antiphospholipid antibodies in childhood. 128
2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative 128
Type I interferon pathway activation in COPA syndrome 127
Adapted versions of the Sharp-van Der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis 126
Clinical assessment in juvenile dermatomyositis. 125
Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis 125
Discordance between proxy-reported and observed assessment of functional ability of children with juvenile idiopathic arthritis. 125
Development and initial validation of composite parent and child centered disease assessment indices for juvenile idiopathic arthritis. 125
Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis 124
Towards a role of ultrasound in children with juvenile idiopathic arthritis. 123
Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: A randomised trial 123
Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology 123
A positive family history of psoriasis does not affect the clinical expression and course of juvenile idiopathic arthritis patients with oligoarthritis. 122
Level of agreement between children, parents and physicians in rating pain intensity in juvenile idiopathic arthritis. 122
Discordance between physician’s and parent’s global assessments in juvenile idiopathic arthritis 122
Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis. 122
Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care 122
The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 122
Evaluation of response to methotrexate by a functional index in juvenile chronic arthritis. 121
EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. 121
Variation of serum IgG subclass concentrations with disease activity in juvenile chronic arthritis. 121
Advances in biomarkers for paediatric rheumatic diseases 121
Use of the Sharp and Larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis. 121
Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease 120
Chronic recurrent multifocal osteomyelitis with unusual features. 120
Preliminary definition of improvement in juvenile arthritis. 120
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. 120
Development and testing of reduced joint counts in juvenile idiopathic arthritis. 119
A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report 119
Unraveling the phenotypic variability of juvenile idiopathic arthritis across races or geographic areas - Key to understanding etiology and genetic factors? 119
Delineating the application of ultrasound in detecting synovial abnormalities of subtalar joint in juvenile idiopathic arthritis 119
Antiphospholipid antibody associated thrombosis in juvenile chronic arthritis. 118
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects 118
Impact of involvement of individual joint groups on subdimensions of functional ability scales in juvenile idiopathic arthritis 117
Antinuclear antibody positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. 117
Macrophage activation syndrome 117
Cytokines in juvenile rheumatoid arthritis. 117
Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study. 117
Development and validation of a composite disease activity score for juvenile idiopathic arthritis 117
Clinical outcome measures in juvenile idiopathic arthritis 117
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation collaborative initiative 117
Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis. 116
Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. 116
Antiphospholipid antibody syndrome as a cause of venous thrombosis in childhood. 115
Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. 115
It is worth including assessment of disease activity state in juvenile arthritis clinical trials. 115
Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. 115
IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis 115
Advances and challenges in imaging in juvenile idiopathic arthritis. 114
Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis 114
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 113
An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis 112
Totale 13.227
Salva come PNG Salva come JPEG
Categoria #
all - tutte 124.826
article - articoli 122.590
book - libri 0
conference - conferenze 192
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.044
Totale 249.652
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207.633 0 0 0 0 0 929 1.880 729 890 1.766 1.069 370
2020/20213.115 145 236 191 452 138 271 234 245 317 379 216 291
2021/20224.971 140 375 514 351 315 194 366 1.135 202 449 291 639
2022/20234.928 524 307 56 387 818 876 39 490 904 41 414 72
2023/20242.367 143 382 48 265 218 351 133 148 98 80 120 381
2024/20253.103 173 636 314 445 807 728 0 0 0 0 0 0
Totale 38.477